Latest News From Lumira Ventures

Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy

Jennifer Schram G1 Therapeutics, Main Page, Portfolio News, Press Release

– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from …

Bardy Diagnostics™ Selected as Winner of the MedTech Breakthrough Award For Best New Diagnostic Technology

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, June 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health …

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development SOUTH SAN FRANCISCO, Calif., May 29, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a Phase 3-stage biopharmaceutical company developing STS101, …

Bardy Diagnostics™ Selected as Winner of the Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, May 7, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced it has been selected as the winner of the North American Remote Cardiac Monitoring Technology Innovation Award by Frost & …

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical …

Bardy Diagnostics™ Announces $35.5M in Series B Funding Round

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, April 16, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion …

Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

admin Aurinia Pharmaceuticals, Main Page, Portfolio News

Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have the potential to protect voclosporin’s method of use and dosing protocol for LN until December 2037 …

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

admin Aurinia Pharmaceuticals, Main Page, Portfolio News

VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis® subjects (p=.0055) demonstrated ≥ 10mm improvement in STT at Week 4 Primary endpoint of drop discomfort at 1-minute on Day …